Table 3.
Current ongoing clinical trial therapeutics of tau.
| Therapy Type | Name | Under | Status |
|---|---|---|---|
| Passive immunotherapies | RO7105705 | Alzheimer’s Disease | Phase 2 |
| Passive immunotherapies | JNJ63733657 | Mild AD | Phase 2 |
| Passive immunotherapies | UCB0107 | Progressive Supranuclear Palsy, Alzheimer’s Disease | PSP (Phase 1), AD (Phase 2) |
| Passive immunotherapies | PNT001 | Alzheimer’s Disease, Traumatic Brain Injury | AD (Phase 1), TBI (Phase 1) |
| Passive immunotherapies | E2814 | Alzheimer’s Disease | Alzheimer’s Disease (Phase 1/2) |
| Passive immunotherapies | LUAF87908 | Alzheimer’s Disease | Phase 1 |
| Active Immunotherapies | AADvac-1 | AD, Progressive Nonfluent Aphasia | AD (Phase 2), PNA (Phase 1) |
| Active Immunotherapies | ACI-35 | AD | Phase 2 |
| Tau Aggregation Inhibitors (TAI) | Methylene Blue (LMTM) | AD, Frontotemporal Dementia | AD (Phase 3), FTD (Phase 3) |
| Post-translational modification aimed at tau | Lithium | MCI (Phase 4), | (Phase 4) |
| Sodium selenate | AD | (Phase 2) |